Companies in the field of bladder cancer typically engage in research, development, clinical trials, and the manufacturing of pharmaceuticals or medical devices related to the diagnosis, treatment, or management of bladder cancer.
CG Oncology: Their oncolytic virus therapy, cretostimogene grenadenorepvec, received both FDA Fast Track and Breakthrough Therapy designations for high-grade non-muscle invasive bladder cancer (NMIBC), potentially offering a novel treatment option with accelerated approval pathway.
AstraZeneca: Initiated Phase 3 trials for their PARP inhibitor, olaparib, in combination with standard chemotherapy for muscle-invasive bladder cancer, aiming to improve survival outcomes.
Bayer Collaborated with a research institution to develop novel antibacterial coatings for medical devices used in bladder cancer procedures, potentially reducing infection risks.
Roche Their TECENTRIQ® (atezolizumab) received US FDA approval for first-line treatment of locally advanced or metastatic urothelial carcinoma, expanding treatment options for bladder cancer patients.
Merck Announced a new manufacturing agreement for Bacillus Calmette-Guérin (BCG), a critical therapy for NMIBC, addressing the global shortage and ensuring patient access.
Medtronic Introduced their latest BlueTouch™ electrocautery system designed for improved precision and tissue preservation in robotic bladder cancer surgery.
Myovant Sciences Their GnRH antagonist, relugolix, is undergoing Phase 3 trials for non-surgical pain management in advanced bladder cancer, offering a potential alternative to invasive procedures.
Bladder Cancer Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)